Evidence map›Paper›PMID 34045960›Full record

ArticleFrontiers in pharmacology2021

Development of a Virtual Chinese Pediatric Population Physiological Model Targeting Specific Metabolism and Kidney Elimination Pathways.

Xueting Yao, Xuanlin Liu, Siqi Tu, Xiaobei Li, Zihan Lei, Zhe Hou, Zhiheng Yu, Cheng Cui, Zhongqi Dong, Farzaneh Salem and 2 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Xueting YaoDrug Clinical Trial Center, Peking University Third Hospital, Beijing, China.
Xuanlin LiuDrug Clinical Trial Center, Peking University Third Hospital, Beijing, China.
Siqi TuDrug Clinical Trial Center, Peking University Third Hospital, Beijing, China.
Xiaobei LiDrug Clinical Trial Center, Peking University Third Hospital, Beijing, China.
Zihan LeiDrug Clinical Trial Center, Peking University Third Hospital, Beijing, China.
Zhe HouDrug Clinical Trial Center, Peking University Third Hospital, Beijing, China.
Zhiheng YuDrug Clinical Trial Center, Peking University Third Hospital, Beijing, China.
Cheng CuiDrug Clinical Trial Center, Peking University Third Hospital, Beijing, China.
Zhongqi DongJanssen China R&D Center, Shanghai, China.
Farzaneh SalemCertara UK Limited, Simcyp Division, Sheffield, United Kingdom.
Haiyan LiDrug Clinical Trial Center, Peking University Third Hospital, Beijing, China.
Dongyang LiuDrug Clinical Trial Center, Peking University Third Hospital, Beijing, China.
Peking University · CNPeking University Third Hospital · CNSimcyp (United Kingdom) · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Chinese pediatric populationCYP1A2CYP3A4PBPKpharmacokineticsrenal elimination

Identifiers

PMID34045960
PMCPMC8145459
OpenAlexW3163113605

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.